跳至主要内容
临床试验/NCT01321268
NCT01321268终止不适用

Safety and Efficacy of an Antioxidant Based Dietary Supplement With PUFAs in Healthy Female Volunteers With Cellulite (Orange Peel Skin)

dsm-firmenich Switzerland AG1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2011年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
发起方
入组人数
8
试验地点
1
主要终点
vital signs

研究概览

简要总结

To investigate the safety and efficacy of a dietary supplement on cellulite alleviation, fat deposits and quality of life.

详细描述

The study will be conducted as a single centre, randomized, double-blind, controlled, parallel group study with healthy female volunteers, aged 18-45 years of age, with skin phototypes I to VI and a clinical diagnosis of cellulite on buttocks (at least score 6 at Cellulite Severity Scale (CSS)).

The study will take 24 weeks (6 months) per subject. There will be one previsit during the screening phase and 8 visits per subject during the treatment phase.

Safety and efficacy variables will be performed monthly.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy female volunteers
  • Age between 18 and 45 years at Day 01 of the study
  • Body mass index (BMI) from 18.5 -24.9
  • All Fitzpatrick skin types
  • CSS score of at least 6
  • Normal eating habits (no vegetarians or vegans)
  • Written informed consent

排除标准

  • Menopause and pre-menopause
  • Pregnant women or women intending to become pregnant during study
  • Lactation period
  • Any kind of dermatological conditions
  • Vegetarians or vegans
  • Any kind of hepatitis, including any alteration in transaminases
  • Use of illicit drugs
  • Other surgical or internal diseases e.g. a metabolic or endocrine disease that may affect the outcome of the study (e.g. diabetes, liver diseases, kidney disorders) or having a history of medical or surgical events that may significantly affect the study outcome including any cardiovascular disease, skin disease, hypertension (>160/95 mm Hg at repeated measurements)
  • Existence of scars and/or pigmentation in measurement areas (thighs and buttocks), which can influence study measurements
  • Participation in any other clinical trial including blood sampling and/or administration or substances up to 30 days before Day 01 of this study
  • Any prior aesthetic surgery (Liposuction, Subcision®), 3 months before the study, that may interfere with results
  • Any other prior anti-cellulite treatment or body measures treatment, 30 days prior to the study
  • Participation in any other non-invasive clinical trial up to 30 days before Day 01 of this study, including blood sampling
  • Recent blood or plasmapherese donation (less than 1 month prior to Day 01 of the study)
  • Under medical treatment for a skin disease in the past and/or present with a therapy, which may influence the results of the study (systemic steroids or antibiotics, local steroids or topical immunomodulators during the last 3 months
  • Use of sun beds or self-tanning products or sun exposure for one month before and during study
  • Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner
  • Subjects intending to initiate any intensive sports
  • Every other condition that the investigator might consider to involve a risk for the study subject.

研究组 & 干预措施

dietary supplement for cellulite

Experimental

PUFA, resveratrol, lycopene, beta carotene, lutein

干预措施: dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein) (Dietary Supplement)

Control

Active Comparator

Vitamin E

干预措施: Viatmin E (Dietary Supplement)

结局指标

主要结局

vital signs

时间窗: 6 months

change in clinical examination at 6 months vs baseline

Clinical biochemistry (hematology, blood chemistry, blood coagulation)

时间窗: 6 months

change in clinical biochemistry at 6 months vs baseline

adverse events and tolerability

时间窗: 6 months

change in number of persons with adverse events at 6 months vs baseline

次要结局

  • corneometry(day 1, 90, 180)
  • Digital photography(Day 1, Day 90, Day 180)
  • satisfaction questionnaire(Day 1, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180)
  • dermatology life quality index(day 1, 30, 60, 90, 120, 150, 180)
  • cutometry(day 1, 90, 180)
  • cellulite severity(Day 1, 7, 30, 60, 90, 120, 150, 180)
  • Thigh circumference(Day 1, 7, 30, 60, 90, 120, 150, 180)
  • Ultrasound sonography(Day 1, Day 90 and Day 180)
  • Magnetic resonance(Day 1 and Day 180)
  • celluquol questionnaire(day 1, 30, 60, 90, 120, 150, 180)
  • skin profilometry(day 1, 90, 180)
  • liquichip analysis(day 1, day 180)

研究者

发起方
dsm-firmenich Switzerland AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验